Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.31 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.31 |
| ▸ | ADA | P00813 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAPDH | P04406 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186054 | 0.90 | ADORA2A (0.35) | ADORA2APDE4DPDE3ASLC29A1HSPA8 | |
| SCHEMBL882508 | 0.90 | ADORA2A (0.35) | ADORA2APDE4DPDE3ASLC29A1HSPA8 | |
| SCHEMBL10149705 | 0.87 | KDM4E (0.35) | ADORA2APDE4DPDE3ASLC29A1SLC28A2 | |
| SCHEMBL881383 | 0.87 | KDM4E (0.35) | ADORA2APDE4DPDE3ASLC29A1SLC28A2 | |
| SCHEMBL10149701 | 0.85 | PDE4D (0.35) | ADORA2APDE4DPDE3ASLC29A1ADA | |
| SCHEMBL881370 | 0.85 | PDE4D (0.35) | ADORA2APDE4DPDE3ASLC29A1ADA | |
| SCHEMBL881381 | 0.83 | ADORA2A (0.40) | ADORA2ASLC29A1SLC28A2HSPA8ADK | |
| SCHEMBL10149698 | 0.83 | ADORA2A (0.40) | ADORA2ASLC29A1SLC28A2HSPA8ADK | |
| SCHEMBL19229290 | 0.80 | PDE4D (0.34) | ADORA2APDE4DPDE3ASLC29A1HSPA8 | |
| SCHEMBL19229338 | 0.80 | PDE4D (0.34) | ADORA2APDE4DPDE3ASLC29A1HSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973013-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, CDA | ADORA2A 109/4885PDE4D 1822/4885PDE3A 2615/4885 |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, RNGTT, SLC29A1 | ADORA2A 149/4885PDE4D 2376/4885PDE3A 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.